Are you Dr. Abrey?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 646-227-3813
Summary
- Dr. Lauren Abrey, MD is a board certified neurologist in New York, New York. She is currently licensed to practice medicine in New York.
Education & Training
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Neurology, 1992 - 1994
- Emory University School of MedicineResidency, Neurology, 1991 - 1992
- Providence HospitalInternship, Internal Medicine, 1990 - 1991
- Georgetown University School of MedicineClass of 1990
Certifications & Licensure
- NY State Medical License 1995 - 2026
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma Start of enrollment: 1998 Sep 01
- Temozolomide in Treating Patients With Recurrent Malignant Glioma Start of enrollment: 1999 Jun 01
- Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases Start of enrollment: 2001 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 41 citationsLeveraging external data in the design and analysis of clinical trials in neuro-oncology.Rifaquat Rahman, Steffen Ventz, Jon McDunn, Bill Louv, Irmarie Reyes-Rivera
The Lancet. Oncology. 2021-10-01 - 29 citationsPhase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.Thomas Kaley, Katherine S. Panageas, Elena Pentsova, Ingo K. Mellinghoff, Craig Nolan
Annals of Clinical and Translational Neurology. 2020-04-01 - 10 citationsPhase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John G. Kuhn, Kathleen R. Lamborn, Lauren E. Abrey, Lisa M. DeAngelis
Neuro-Oncology Advances. 2020-01-01